November 04, 2025

Imaging Steatosis May Forecast Diabetes

MRI-based liver fat levels tracked insulin resistance and higher glucose readings.

Conexiant

November 04, 2025

GLP-1s and Tirzepatide: Similar GI Risk

Real-world data show similar rates of severe GI events with semaglutide, dulaglutide, and tirzepatide, reinforcing comparable safety across agents in routine care.

Conexiant

October 29, 2025

FDA Pushes Faster, Cheaper Route for Biosimilar Approval

The FDA released new draft guidance to streamline biosimilar development.

Conexiant

October 29, 2025

H-1B Visa Changes: Who Pays the Price?

New fee structure could hit hardest where physicians are needed most.

Conexiant

October 22, 2025

Do GLP-1RAs Differ in Cardiometabolic Protection?

Researchers found that liraglutide and semaglutide offer similar cardiovascular and kidney benefits in type 2 diabetes.

Conexiant

October 15, 2025

Study Describes Patterns in Reported Drug Interactions

Researchers analyze about 177,000 drug interactions to identify key medication safety trends.

Conexiant

October 14, 2025

Do quadruple therapies beat triple for H. pylori?

Concomitant and bismuth quadruple regimens provided substantially higher eradication rates than triple therapy without an adherence penalty.

Conexiant

October 07, 2025

EASO Issues Obesity Pharmacotherapy Guidance

EASO framework guides obesity drug selection by weight loss effect and complication focus.

Conexiant

September 05, 2025

Ancillary Features Don’t Improve LI-RADS Accuracy

The study raises questions about whether ancillary features still warrant inclusion in liver imaging workflows.

Conexiant